Adult Dosing

Cycloplegia/mydriasis

• 1-2 gtt in eye(s) x1; repeat q5-10 mins if necessary
• Note: Apply pressure over the nasolacrimal sac for 2-3 mins.

Pediatric Dosing

Cycloplegia/mydriasis

• Small infants: 1 gtt of 0.5% soln in eye(s) x1
• Note: Apply pressure over the nasolacrimal sac for 2-3 mins. Observe infant closely for at least 30 minutes following instillation
• Pediatrics: 1-2 gtt in eye(s) x1; repeat q5-10 mins by a second application of 0.5% or 1% solution if necessary

[Outline]

• Adult Dosing
• Pediatric Dosing

• For producing mydriasis and cycloplegia

• Hypersensitivity to any of the ingredients of the product
• Presence of untreated narrow-angle glaucoma
• Presence of untreated anatomically narrow angles

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• For topical ophthalmic use only. Avoid using as an injection
• CNS disturbances may be induced by this preparation especially in younger age groups; but these have occurred in all age groups, especially with the stronger solutions. Infants are especially susceptible to CNS and cardiopulmonary side effects
• Use only 1 drop of 0.5% solution per eye followed by compressing lacrimal sac by digital pressure for 2-3 minutes after instillation to reduce excessive systemic absorption. Closely observe infants for at least 30 minutes following instillation
• May produce a transient elevation of intraocular pressure

Cautions: Use cautiously in

• Infants
• Young children
• Geriatric patients
• Down syndrome
• Brain damage (pediatric patients)
• Spastic paralysis (pediatric patients)

Supplemental Patient Information

• Advise patients to avoid touching dropper tip to any surface as this may contaminate the solution
• Advise patients to avoid driving or engaging in other hazardous activities while pupils are dilated
• Instruct patients to protect eyes in bright illumination during dilation
• Warn patients to avoid getting this preparation in their child’s mouth and to wash their own hands and the child’s hands following instillation
• Advise patients to withhold feeding for 4 hours in infants due to the possibility of feeding intolerance following eye drops instillation
• Inform patients that a transient burning sensation may occur following instillation

Pregnancy Category:C

Breastfeeding: Literature unavailable on the use of cyclopentolate during breastfeeding. Anticholinergic drugs might interfere with breastfeeding. A single dose is not likely to interfere with breastfeeding; during prolonged use, observe the infant for signs of decreased lactation (e.g., insatiety, poor weight gain). For substantially diminishing the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 8 February 2011). Manufacturer advises caution.

• PSYCHIATRY: Psychosis, hallucinations, behavioral disturbances
• CNS: Restlessness, hyperactivity, seizures, disorientation, drowsiness, medullary paralysis, coma, failure to recognize people, confusion
• EENT: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae, decreased secretion in nasal passages, eyelid edema
• NEURO: Ataxia, incoherent speech
• DERM: Skin rash, decreased secretion in sweat glands
• GI: Abdominal distention, diminished GI motility, decreased secretion in salivary glands
• CV: Tachycardia, vasodilation, hypotension
• GU: Urinary retention
• RESP: Respiratory depression, decreased secretion in pharynx, bronchi
• MISC: Death, hyperpyrexia

• Anticholingeric, cycloplegic/mydriatic; blocks responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body, produces mydriasis and cycloplegia
• Metabolism: Unknown; CYP450: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Akpentolate
• Cyclogyl
• Pentolair

US Availability

cyclopentolate (generic)

• OPTH SOLN: 1%

Akpentolate

• OPTH SOLN: 1%
• OPTH SOLN: 2%

Cyclogyl

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%
• OPTH SOLN: 2%

Pentolair

• OPTH SOLN: 1%

Canadian Trade Name(s)

• AK pentolate
• Cyclogyl
• Diopentolate

Canadian Availability

cyclopentolate (generic)

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%

AK pentolate

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%

Cyclogyl

• OPTH SOLN: 1%

Diopentolate

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%

UK Trade Name(s)

• Mydrilate

UK Availability

cyclopentolate (generic)

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%

Mydrilate

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%

Australian Trade Name(s)

• Cyclogyl

Australian Availability

cyclopentolate (generic)

• OPTH SOLN: 0.5%
• OPTH SOLN: 1%

Cyclogyl

• OPTH SOLN: 1%

[Outline]

Ophthalmic

Ophthalmic Mydriatics

Pricing data from www.DrugStore.com in U.S.A.

• Cyclopentolate HCl 1 % SOLN [Bottle] (BAUSCH & LOMB)
  15 % = $40.99
  30 % = $69.98

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.